Cargando…
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Uterine cervix cancers pose therapeutic challenges because of an overactive ribonucleotide reductase, which provides on-demand deoxyribonucleotides for DNA replication or for a DNA damage repair response. Ribonucleotide reductase overactivity bestows cancer cell resistance to the effects of radiothe...
Autores principales: | Kunos, Charles A., Capala, Jacek, Kohn, Elise C., Ivy, Susan Percy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607970/ https://www.ncbi.nlm.nih.gov/pubmed/31297338 http://dx.doi.org/10.3389/fonc.2019.00560 |
Ejemplares similares
-
Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019) -
Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files
por: Kunos, Charles A., et al.
Publicado: (2019) -
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019) -
Clinical Outcome Assessments Toolbox for Radiopharmaceuticals
por: Kunos, Charles A., et al.
Publicado: (2019) -
Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Brachytherapy in Puerto Rico After Hurricane Maria
por: Kunos, Charles A., et al.
Publicado: (2019)